Skip to main content
EJNMMI Radiopharmacy and Chemistry
Fig. 1 | EJNMMI Radiopharmacy and Chemistry

Fig. 1

From: Comparing the use of radiolabeled SSTR agonists and an SSTR antagonist in breast cancer: does the model choice influence the outcome?

Fig. 1

Binding and internalization of 111In-DOTA-Tyr3-octreotate and 111In-DOTA-JR11 to the endougenously SSTR expressing cell line ZR75–1 and the SSTR2 transfected cell line U2OS + SSTR2. Cells were incubated for 1 h at 37 °C or 4 °C with 10−9 M of the agonist or the antagonist. The bars represent the percentage added dose (%AD) bound and/or internalized (in)to the cells. The %AD is corrected for unspecific binding determined by blocking studies in which 10−6 M of the unlabeled agonist or antagonist was added

Back to article page